Author Archives: Kemal

About Kemal

A bioprocess engineer, modeler, machine learning dreamer.

Why I Stopped Trusting My Gut (and Started Trusting My Models) — AI in Lysine Fermentation

By | February 19, 2026

Look, I’ll be honest. For years I ran bioreactors the way most of us do: set your temperature, set your pH, watch the DO trace, take a sample every few hours, and hope for the best. You tweak the feed rate because “it feels right.” You crank up the stirrer because the DO is dropping.… Read More: Why I Stopped Trusting My Gut (and Started Trusting My… »

Building ML Tools Scientists Will Actually Use

By | January 25, 2026

The Gap Between Models and Tools I’ve seen a lot of impressive ML models in biopharma that never get used. Not because the science is wrong, but because the tool doesn’t fit into anyone’s workflow. The model might be published in Nature Methods with beautiful receiver operating characteristic curves, but if a discovery scientist can’t… Read More: Building ML Tools Scientists Will Actually Use »

What Makes an Antibody Hard to Manufacture? Data-Driven Insights

By | January 25, 2026

The Features That Matter After training the developability model on 100+ therapeutic antibodies, I looked at the feature importance rankings. The model had learned to weight certain properties more heavily than others when making predictions. Some of these were obvious. Some were surprising. All of them tell us something about what actually makes antibodies difficult… Read More: What Makes an Antibody Hard to Manufacture? Data-Driven Insights »

Case Study: Predicting Trastuzumab Developability

By | January 25, 2026

Why Trastuzumab Is the Perfect Test Case When I built my antibody developability predictor, I knew I needed to validate it against a molecule where we actually know the manufacturing story. Trastuzumab (Herceptin) was the obvious choice. It’s one of the most successful therapeutic antibodies ever made, with decades of manufacturing data behind it. More… Read More: Case Study: Predicting Trastuzumab Developability »

How I Built a Machine Learning Tool to Predict Drug Manufacturing Failures

By | January 25, 2026

A bioprocess engineer’s journey into machine learning and why the pharmaceutical industry desperately needs this bridge When I tell people I work in bioprocess engineering, I usually get blank stares. When I explain that I help manufacture proteins in giant tanks for therapeutic use, the response is often: “Oh, like brewing beer?” Not quite. But… Read More: How I Built a Machine Learning Tool to Predict Drug… »

What AI Product Leadership Actually Means in Life Science R&D

By | January 24, 2026

There’s a specific kind of tension that defines working at the intersection of artificial intelligence and regulated discovery science. It’s not technical. It’s not about model architecture or compute budgets. It’s about the gap between what a model can do and what a scientist will trust enough to use AI product leadership in biopharma R&D… Read More: What AI Product Leadership Actually Means in Life Science R&D »

NIR Biomass Analysis Gone Wrong

By | January 23, 2026

I recently had to audit a production NIR spectroscopy system used for biomass analysis. On paper, it sounded impressive: “state of the art chemometrics,” “advanced multivariate calibration,” “industry ready models.” In reality? It was a textbook example of how to do NIR modeling wrong in ways that quietly transfer risk and liability from the software vendor… Read More: NIR Biomass Analysis Gone Wrong »

From Conventional Design to AI-Driven Innovation: A Strategic Journey in Advanced Manufacturing

By | January 24, 2026

The Inflection Point Three-four years ago, I stood in front of production equipment I’d designed using textbook equations and decades-old heuristics. The systems worked—they always had—but I couldn’t shake the feeling that we were leaving performance on the table. That nagging intuition led me down a rabbit hole of machine learning papers, Python tutorials, and… Read More: From Conventional Design to AI-Driven Innovation: A Strategic Journey in… »